Troglitazone upregulates LDL receptor activity in HepG2 cells

Diabetes

Volumn 47, Issue 8, 1998, Pages 1193-1198

  Al Rayyes, Osama ^a,b   Florén, Claes Henrik ^a  

^a Malmö University Hospital   (Sweden)

^b University Hospital Malmö   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CYCLOSPORIN; DEXTRAN SULFATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; IMMUNOSUPPRESSIVE AGENT; INSULIN; LOW DENSITY LIPOPROTEIN RECEPTOR; TROGLITAZONE;

ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR BINDING; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

CHROMANS; CYCLOSPORINE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPOPROTEINS, LDL; LIVER; RECEPTORS, LDL; RNA, MESSENGER; THIAZOLES; THIAZOLIDINEDIONES; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0008615403     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.47.8.1193     Document Type: Article

References (36)

1. Kraegen EW, James DE, Jenkins AB, Chisholm DJ, Storlien LH: A potent in vivo effect of ciglitazone on muscle insulin resistance induced by high fat feeding of rats. Metabolism 38:1089-1093, 1989
2. Iwanishi M, Kobayashi M: Effect of pioglitazone on insulin receptors of skeletal muscles from high-fat-fed rats. Metabolism 42:1017-1021, 1993
3. Fujiwara T, Yoshioka S, Yoshioka T, Ushiama I, Horikoshi H: Characterization of a new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549-1558, 1988
4. Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA: In vitro studies on the action of CS-045: a new antidiabetic agent. Metabolism 39:1056-1062, 1990
5. Horikoshi H, Fujiwara T, Shimada M, Yoshioka S, Tokui T, Yoshioka T: Suppression of hepatic gluconeogenesis by CS-045 in KK mice and in perfused liver (Abstract). Diabetes 39 (Suppl. 1):111A, 1990
6. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T: Effect of combination therapy of troglitazone and sulphonylureas in patients with type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diabet Med 13:365-370, 1996
7. Antonucci T, Whitcomb R, McLain R, Lockwood D: Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 20:188-193, 1997
8. Mimura K, Umeda F, Hiramatsu S, Taniguchi S, Ono Y, Nakashima N, Kobayashi K, Masakado M, Sako Y, Nawata H: Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabet Med 11:685-691, 1994
9. Kathleen B, Ruth P, Siri LK, Jose G, Aura M, Meleana ED, Anny X, Stanley A, Thomas AB: Effect of troglitazone on insulin sensitivity and pancreatic β-cell function in women at high risk for NIDDM. Diabetes 45:1572-1579, 1996
10. Suter SL, Nolan JJ, Wallace P, Combiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203, 1992
11. Nagasaka Y, Kaku K, Nakamura K, Kaneko T: The new oral hypoglycemic agent, CS-045, inhibits the lipid peroxidation of human plasma low density lipoprotein in vitro. Biochem Pharmacol 50:1109-1111, 1995
12. Cominacini L, Garbin U, Pastorino AM, Campagnola M, Fratta Pasini A, Davoli A, Rigoni A, Lo Cascio V: Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells. Diabetologia 40:165-172, 1997
13. Havel RJ, Hamilton RL: Hepatocytic lipoprotein receptors and intracellular lipoprotein catabolism. Hepatology 8:1689-1704, 1988
14. Havel RJ, Eder HA, Bragdon JH: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34:1345-1353, 1955
15. McFarlane AS: Efficient trace-labelling of proteins with iodine. Nature 182:53, 1958
16. Bierman EL, Stein O, Stein Y: Lipoprotein uptake and metabolism by aortic smooth muscle cells in tissue culture. Circ Res 35:136-150, 1974
17. Salter AM, Saxton J, Brindley D: Characterization of the binding of human low-density lipoprotein to primary monolayer cultures of rat hepatocytes. Biochem J 240:549-557, 1986
18. Ausubel MA, Bernt R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K: Preparation and analysis of RNA. In Current Protocols in Molecular Biology. Cambridge, MA, Green Publishing, Wiley, 1993, p. 1:4.0.1-1.10.9
19. Al Rayyes O, Wallmark A, Florén C-H: Additive inhibitory effect of hydrocortisone and cyclosporine on low-density lipoprotein receptor activity in cultured HepG2 cells. Hepatology 26:967-971, 1997
20. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurements with folin phenol reagents. J Biol Chem 193:265-275, 1951
21. Afifi AA, Azen SP: Statistical Analysis: A Computer Oriented Approach, 2nd ed. New York, Academic Press, 1977
22. Norusis MJ: SPSS for Windows, Release 6.0. Chicago, SPSS, 1993
23. Wade DP, Knight BL, Soutar AK: Hormonal regulation of low-density lipoprotein (LDL) receptor activity in human hepatoma Hep G2 cells: insulin increases LDL receptor activity and diminishes its suppression by exogenous LDL. Eur J Biochem 174:213-218, 1988
24. Wade DP, Knight BL, Soutar AK: Regulation of low-density lipoprotein-mRNA by insulin in human hepatoma Hep G2 cells. Eur J Biochem 181:727-731, 1989
25. Chait A, Bierman EL, Albers JJ: Regulatory role of insulin in the degradation of low density lipoprotein by cultured human skin fibroblasts. Biochim Biophys Acta 529:292-299, 1978
26. Chait A, Bierman EL, Albers JJ: Low density lipoprotein receptor activity in cultured human skin fibroblasts: mechanism of insulin-induced stimulation. J Clin Invest 64:1309-1319, 1979
27. Ellsworth JL, Erickson SK, Cooper AD: Very low and low density lipoprotein synthesis and secretion by the human hepatoma cell line Hep G2 cells: effect of free fatty acid. J Lipid Res 27:858-874, 1986
28. Wang SR, Pessah M, Infante J, Catala D, Salvat C, Infante R: Lipid and lipoprotein metabolism in HepG2 cells. Biochim Biophys Acta 961:351-363, 1988
29. Podskalny JM, Takeda S, Silverman RE, Tran D, Carpentier JL, Orci L, Gorden P: Insulin receptors and bioresponses in a human liver cell line (HEP G2). Eur J Biochem 150:401-407, 1985
30. Al Rayyes O, Wallmark A, Florén C-H: Reversal of cyclosporine inhibited low density lipoprotein receptor activity in Hep G2 cells by 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors. Hepatology 25:991-994, 1997
31. Park KS, Ciaraldi TP, Abrams-Carter L, Mudaliar S, Nikoulina SE, Henry RR: PPAR-γ gene expression is elevated in skeletal muscle of obese and type II diabetes subjects. Diabetes 46:1230-1234, 1997
32. Shalev A, Siegrist-Kaiser CA, Yen PM, Wahli W, Burger AG, Chin WW, Meier CA: The peroxisome proliferator-activated receptor a is a phosphoprotein: regulation by insulin. Endocrinology 137:4499-4502, 1996
33. Zhang B, Berger J, Zhou G, Elbrecht A, Biswas S, White-Carrington S, Szalkowski D, Moller DE: Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor γ. J Biol Chem 271:31771-31774, 1996
34. Al Rayyes O, Wallmark A, Florén C-H: Cyciosporine inhibits catabolism of low-density lipoproteins in HepG2 cells by 25%. Hepatology 24:613-619, 1996
35. Spiera H, Rothenberg RR: Myocardial infarction in four young patients with SLE. J Rheumatol 10:464-466, 1983
36. Nashel DJ: Is atherosclerosis a complication of long-term corticosteroid treatment? Am J Med 80:925-929, 1986